In our study, multiple DEPs following both treatments (iron nanoparticles: HNRNPH2, HIST2H3A, RPS23, HMGN2, LGALS1; NP-Ab: RPS23, HMGN2, LGALS1, and FEN1) corresponded to proteins that have been previously shown to be altered in neuroblastoma cells treated with FeCl3 [65], suggesting alterations to ferric iron levels in the cells and some nanoparticle degradation occurring at 24 h post-treatment. Here, HMGN2 is linked to neuroblastoma.